Previous 10 | Next 10 |
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the publication of new data in Clinical & Experimental Allergy charact...
KalVista Pharmaceticals press release (NASDAQ:KALV): Q3 GAAP EPS of -$0.92 in-line. Cash, cash equivalents and marketable securities were $194.8 million as of January 31, 2022, compared to $248.9 million as of April 30, 2021. For further details see: KalVista Pharmaceticals GAAP E...
KalVista Pharmaceuticals (NASDAQ:KALV) began a phase 3 trial, dubbed KONFIDENT, evaluating its potential oral drug KVD900 for hereditary angioedema (HAE) attacks. HAE is a disorder characterized by recurrent attacks of severe swelling of the skin and mucous membranes. The company sa...
-KONFIDENT to Evaluate KVD900 As First Oral On-Demand Therapy for HAE- -KONFIDENT Designed to Support Broad Label for Treatment of All HAE Attacks- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, develo...
– KVD900 Phase 2 data presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Scientific Meeting – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and com...
KalVista Pharmaceuticals (NASDAQ:KALV) announced that the compensation committee of its board granted four newly-hired employees inducement options to purchase 19K shares. The options have an exercise price of $12.72/share, equivalent to closing price of KalVista common stock o...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that new data on KVD900, KalVista’s lead drug program for oral on-deman...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data from the Phase 1 clinical trials of oral, on-demand treatment KVD900 in patient...
KalVista Pharmaceuticals (NASDAQ:KALV) compensation committee granted 6 newly-hired employees inducement options to purchase an aggregate of 18,000 shares on December 1, 2021 The options have an exercise price of $13.63 per share One-fourth of the options vest on the one-year anniversar...
The following slide deck was published by KalVista Pharmaceuticals, Inc. in conjunction with this event. For further details see: Kalvista Pharmaceuticals (KALV) Investor Presentation - Slideshow
News, Short Squeeze, Breakout and More Instantly...
KalVista Pharmaceuticals Inc. Company Name:
KALV Stock Symbol:
NASDAQ Market:
KalVista Pharmaceuticals Inc. Website:
2024-07-12 17:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged...
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) a...